Pharmacokinetics of Deferiprone in Patients with β-Thalassaemia: Impact of Splenectomy and Iron Status

Author： >  

Publisher： Adis International

ISSN： 0312-5963

Source： Clinical Pharmacokinetics, Vol.50, Iss.1, 2011-01, pp. : 41-50

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacoeconomic Considerations in Treating Iron Overload in Patients with β-Thalassaemia, Sickle Cell Disease and Myelodysplastic Syndromes in the US: A Literature Review

By Zhang Bin  

PharmacoEconomics, Vol. 29, Iss. 6, 2011-06 ,pp. : 461-474

Adis International

Access to resources Recommend Favorite

Red Cell Indices and Functions Differentiating Patients with the β-Thalassaemia Trait from those with Iron Deficiency Anaemia

By Okan V   Cigiloglu A   Cifci S   Yilmaz M   Pehlivan M  

The Journal of International Medical Research, Vol. 37, Iss. 1, 2009-01 ,pp. : 25-30

Field House Publishing

Access to resources Recommend Favorite

Deferiprone vs deferoxamine in thalassaemia

By  

Inpharma, Vol. 1, Iss. 1352, 2002-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Benefits and Risks of Deferiprone in Iron Overload in Thalassaemia and Other Conditions: Comparison of Epidemiological and Therapeutic Aspects with Deferoxamine

By Kontoghiorghes G.J.   Neocleous K.   Kolnagou A.  

Drug Safety, Vol. 26, Iss. 8, 2003-01 ,pp. : 553-584

Adis International

Access to resources Recommend Favorite

Case report: PGD of β-thalassaemia and HLA haplotypes using OmniPlex whole genome amplification

By Chen Shee-Uan   Su Yi-Ning   Fang Mei-Ya   Chang Li-Jung   Tsai Yi-Yi   Lin Li-Ting   Lee Chien-Nan   Yang Yu-Shih  

Reproductive BioMedicine Online, Vol. 17, Iss. 5, 2008-11 ,pp. : 699-705

Reproductive Healthcare Ltd

Access to resources Recommend Favorite